BIOMAT Database Logo BIOMAT Database Logo

Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. 1987

L R Levine, and S Rosenblatt, and J Bosomworth
Lilly Research Laboratories, Indianapolis, Indiana 46285.

Health risks associated with obesity are well known and compliance with standard regimens for weight reduction is frequently unsatisfactory. Fluoxetine is a specific inhibitor of serotonin re-uptake with very minimal affinity for serotonergic or other receptors. It causes a decrement in food intake in animals. Placebo or fluoxetine was given for up to 8 weeks to non-depressed, otherwise healthy, obese patients given minimal dietary advice. Patients given fluoxetine lost 4.5 +/- 4.0 kg, significantly more than those receiving placebo, 1.4 +/- 0.1 kg. The weight loss was correlated with the degree of obesity in the fluoxetine-treated patients. Asthenia was the only event reported significantly more frequently by fluoxetine-treated patients (23 percent) than by those treated with placebo (3 percent) (P less than 0.01). Fluoxetine appears to be safe and effective in inducing weight loss over periods of up to 8 weeks.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D011437 Propylamines Derivatives of propylamine (the structural formula NH2CH2CH2CH3).
D005260 Female Females
D005473 Fluoxetine The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. Fluoxetin,Fluoxetine Hydrochloride,Lilly-110140,N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine,Prozac,Sarafem,Lilly 110140,Lilly110140
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

L R Levine, and S Rosenblatt, and J Bosomworth
Fluoxetine, a selective serotonin uptake inhibitor.
April 1978, Clinical pharmacology and therapeutics,
L R Levine, and S Rosenblatt, and J Bosomworth
Fluoxetine, a selective inhibitor of serotonin uptake.
January 1991, Medicinal research reviews,
L R Levine, and S Rosenblatt, and J Bosomworth
Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub).
January 1989, International journal of obesity,
L R Levine, and S Rosenblatt, and J Bosomworth
Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression.
April 1988, Journal of clinical psychopharmacology,
L R Levine, and S Rosenblatt, and J Bosomworth
Molecular structure of fluoxetine hydrochloride, a highly selective serotonin-uptake inhibitor.
January 1988, Journal of medicinal chemistry,
L R Levine, and S Rosenblatt, and J Bosomworth
Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity.
March 1991, International journal of obesity,
L R Levine, and S Rosenblatt, and J Bosomworth
[The influence of selective serotonin re-uptake inhibitor fluoxetine on inotropic function of myocardium in the ontogenesis of rats].
March 2014, Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova,
L R Levine, and S Rosenblatt, and J Bosomworth
Alterations of central hypercapnic respiratory response induced by acute central administration of serotonin re-uptake inhibitor, fluoxetine.
October 2011, The Chinese journal of physiology,
L R Levine, and S Rosenblatt, and J Bosomworth
Inhibition of REM sleep by fluoxetine, a specific inhibitor of serotonin uptake.
June 1978, Neuropharmacology,
L R Levine, and S Rosenblatt, and J Bosomworth
Environmental risk assessment for the serotonin re-uptake inhibitor fluoxetine: Case study using the European risk assessment framework.
July 2010, Integrated environmental assessment and management,
Copied contents to your clipboard!